GlassScriptPhysician profile
Margaret Ann Colleran
NPI 1457356677
$6,849.55
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $1,021 · 2021: $1,413 · 2022: $776 · 2023: $1,126 · 2024: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $648.94 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $612.84 | 2019-2024 | Rybelsus, Ozempic, Saxenda |
| Abbvie INC. | $543.87 | 2019-2024 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $488.70 | 2019-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $485.77 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.01 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $295.82 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $291.90 | 2021-2024 | |
| Amarin Pharma, INC. | $289.73 | 2019-2021 | |
| Pfizer INC. | $232.16 | 2019-2024 | |
| Exact Sciences Corporation | $202.78 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $199.93 | 2019-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $189.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $180.16 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Radius Health, INC. | $173.53 | 2019-2024 | Tymlos |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Colleran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.